Literature DB >> 33258947

Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models.

Ming Yuan1, David White2, Linda Resar3, Eli Bar4, Mari Groves5, Alan Cohen5, Eric Jackson5, Jennifer Bynum1, Jeffrey Rubens3, Jeff Mumm2, Liam Chen1, Liqun Jiang1, Eric Raabe1, Fausto J Rodriguez1, Charles G Eberhart1.   

Abstract

BACKGROUND: The conditional reprogramming cell culture method was developed to facilitate growth of senescence-prone normal and neoplastic epithelial cells, and involves co-culture with irradiated fibroblasts and the addition of a small molecule Rho kinase (ROCK) inhibitor. The aim of this study was to determine whether this approach would facilitate the culture of compact low-grade gliomas.
METHODS: We attempted to culture 4 pilocytic astrocytomas, 2 gangliogliomas, 2 myxopapillary ependymomas, 2 anaplastic gliomas, 2 difficult-to-classify low-grade neuroepithelial tumors, a desmoplastic infantile ganglioglioma, and an anaplastic pleomorphic xanthoastrocytoma using a modified conditional reprogramming cell culture approach.
RESULTS: Conditional reprogramming resulted in robust increases in growth for a majority of these tumors, with fibroblast conditioned media and ROCK inhibition both required. Switching cultures to standard serum containing media, or serum-free neurosphere conditions, with or without ROCK inhibition, resulted in decreased proliferation and induction of senescence markers. Rho kinase inhibition and conditioned media both promoted Akt and Erk1/2 activation. Several cultures, including one derived from a NF1-associated pilocytic astrocytoma (JHH-NF1-PA1) and one from a BRAF p.V600E mutant anaplastic pleomorphic xanthoastrocytoma (JHH-PXA1), exhibited growth sufficient for preclinical testing in vitro. In addition, JHH-NF1-PA1 cells survived and migrated in larval zebrafish orthotopic xenografts, while JHH-PXA1 formed orthotopic xenografts in mice histopathologically similar to the tumor from which it was derived.
CONCLUSIONS: These studies highlight the potential for the conditional reprogramming cell culture method to promote the growth of glial and glioneuronal tumors in vitro, in some cases enabling the establishment of long-term culture and in vivo models.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  BRAFV600E; NF1; conditional reprogramming; enescence; low-grade glioma

Mesh:

Substances:

Year:  2021        PMID: 33258947      PMCID: PMC8099469          DOI: 10.1093/neuonc/noaa263

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  48 in total

Review 1.  The Zebrafish Xenograft Platform: Evolution of a Novel Cancer Model and Preclinical Screening Tool.

Authors:  Jaime Wertman; Chansey J Veinotte; Graham Dellaire; Jason N Berman
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

2.  Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.

Authors:  Brad Poore; Ming Yuan; Antje Arnold; Antoinette Price; Jesse Alt; Jeffrey A Rubens; Barbara S Slusher; Charles G Eberhart; Eric H Raabe
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

3.  ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells.

Authors:  Xuefeng Liu; Virginie Ory; Sandra Chapman; Hang Yuan; Chris Albanese; Bhaskar Kallakury; Olga A Timofeeva; Caitlin Nealon; Aleksandra Dakic; Vera Simic; Bassem R Haddad; Johng S Rhim; Anatoly Dritschilo; Anna Riegel; Alison McBride; Richard Schlegel
Journal:  Am J Pathol       Date:  2011-12-18       Impact factor: 4.307

4.  Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens.

Authors:  Xuefeng Liu; Ewa Krawczyk; Frank A Suprynowicz; Nancy Palechor-Ceron; Hang Yuan; Aleksandra Dakic; Vera Simic; Yun-Ling Zheng; Praathibha Sripadhan; Chen Chen; Jie Lu; Tung-Wei Hou; Sujata Choudhury; Bhaskar Kallakury; Dean G Tang; Thomas Darling; Rajesh Thangapazham; Olga Timofeeva; Anatoly Dritschilo; Scott H Randell; Christopher Albanese; Seema Agarwal; Richard Schlegel
Journal:  Nat Protoc       Date:  2017-01-26       Impact factor: 13.491

5.  BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Authors:  Chrysiis Michaloglou; Liesbeth C W Vredeveld; Maria S Soengas; Christophe Denoyelle; Thomas Kuilman; Chantal M A M van der Horst; Donné M Majoor; Jerry W Shay; Wolter J Mooi; Daniel S Peeper
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

6.  Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.

Authors:  Chuan Yan; Dalton C Brunson; Qin Tang; Daniel Do; Nicolae A Iftimia; John C Moore; Madeline N Hayes; Alessandra M Welker; Elaine G Garcia; Taronish D Dubash; Xin Hong; Benjamin J Drapkin; David T Myers; Sarah Phat; Angela Volorio; Dieuwke L Marvin; Matteo Ligorio; Lyle Dershowitz; Karin M McCarthy; Murat N Karabacak; Jonathan A Fletcher; Dennis C Sgroi; John A Iafrate; Shyamala Maheswaran; Nick J Dyson; Daniel A Haber; John F Rawls; David M Langenau
Journal:  Cell       Date:  2019-04-25       Impact factor: 41.582

7.  The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma.

Authors:  Juliane L Buhl; Florian Selt; Thomas Hielscher; Romain Guiho; Jonas Ecker; Felix Sahm; Johannes Ridinger; Dennis Riehl; Diren Usta; Britta Ismer; Alexander C Sommerkamp; J P Martinez-Barbera; Annika K Wefers; Marc Remke; Daniel Picard; Stefan Pusch; Jan Gronych; Ina Oehme; Cornelis M van Tilburg; Marcel Kool; Daniela Kuhn; David Capper; Andreas von Deimling; Martin U Schuhmann; Christel Herold-Mende; Andrey Korshunov; Tilman Brummer; Stefan M Pfister; David T W Jones; Olaf Witt; Till Milde
Journal:  Clin Cancer Res       Date:  2018-12-07       Impact factor: 12.531

8.  Δ133p53α, a natural p53 isoform, contributes to conditional reprogramming and long-term proliferation of primary epithelial cells.

Authors:  Abdul M Mondal; Hua Zhou; Izumi Horikawa; Frank A Suprynowicz; Guangzhao Li; Aleksandra Dakic; Bernard Rosenthal; Lin Ye; Curtis C Harris; Richard Schlegel; Xuefeng Liu
Journal:  Cell Death Dis       Date:  2018-07-03       Impact factor: 8.469

9.  Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development.

Authors:  Dorine A Bax; Suzanne E Little; Nathalie Gaspar; Lara Perryman; Lynley Marshall; Marta Viana-Pereira; Tania A Jones; Richard D Williams; Anita Grigoriadis; Gilles Vassal; Paul Workman; Denise Sheer; Rui M Reis; Andrew D J Pearson; Darren Hargrave; Chris Jones
Journal:  PLoS One       Date:  2009-04-14       Impact factor: 3.240

10.  Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth.

Authors:  Yuan Pan; Min Xiong; Ran Chen; Yu Ma; Courtney Corman; Meron Maricos; Urs Kindler; Marcus Semtner; Yi-Hsien Chen; Sonika Dahiya; David H Gutmann
Journal:  Genes Dev       Date:  2018-04-09       Impact factor: 11.361

View more
  7 in total

1.  Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas.

Authors:  Christopher M Rota; Alexander T Brown; Emily Addleson; Clara Ives; Ella Trumper; Kristine Pelton; Wei Pin Teh; Matthew J Schniederjan; Robert Craig Castellino; Sara Buhrlage; Douglas A Lauffenburger; Keith L Ligon; Linda G Griffith; Rosalind A Segal
Journal:  Neurooncol Adv       Date:  2022-04-13

2.  Therapeutic Vulnerability to ATR Inhibition in Concurrent NF1 and ATRX-Deficient/ALT-Positive High-Grade Solid Tumors.

Authors:  Ming Yuan; Charles G Eberhart; Christine A Pratilas; Jaishri O Blakeley; Christine Davis; Marija Stojanova; Karlyne Reilly; Alan K Meeker; Christopher M Heaphy; Fausto J Rodriguez
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

3.  Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation.

Authors:  Amanda de Andrade Costa; Jit Chatterjee; Olivia Cobb; Elizabeth Cordell; Astoria Chao; Suzanne Schaeffer; Andrea Goldstein; Sonika Dahiya; David H Gutmann
Journal:  Neurooncol Adv       Date:  2021-12-31

4.  Establishment of patient-derived organoid models of lower-grade glioma.

Authors:  Kalil G Abdullah; Cylaina E Bird; Joseph D Buehler; Lauren C Gattie; Milan R Savani; Alex C Sternisha; Yi Xiao; Michael M Levitt; William H Hicks; Wenhao Li; Denise M O Ramirez; Toral Patel; Tomas Garzon-Muvdi; Samuel Barnett; Gao Zhang; David M Ashley; Kimmo J Hatanpaa; Timothy E Richardson; Samuel K McBrayer
Journal:  Neuro Oncol       Date:  2022-04-01       Impact factor: 13.029

5.  Human induced pluripotent stem cell engineering establishes a humanized mouse platform for pediatric low-grade glioma modeling.

Authors:  Corina Anastasaki; Jit Chatterjee; Olivia Cobb; Shilpa Sanapala; Suzanne M Scheaffer; Amanda De Andrade Costa; Anna F Wilson; Chloe M Kernan; Ameera H Zafar; Xia Ge; Joel R Garbow; Fausto J Rodriguez; David H Gutmann
Journal:  Acta Neuropathol Commun       Date:  2022-08-19       Impact factor: 7.578

Review 6.  Zebrafish Models of Paediatric Brain Tumours.

Authors:  Faiza Basheer; Poshmaal Dhar; Rasika M Samarasinghe
Journal:  Int J Mol Sci       Date:  2022-08-31       Impact factor: 6.208

Review 7.  Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas.

Authors:  Till Milde; Fausto J Rodriguez; Jill S Barnholtz-Sloan; Nirav Patil; Charles G Eberhart; David H Gutmann
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 13.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.